Filing of 10Q form

MXCT 11.07.2024

Full Press ReleaseSEC FilingsOur MXCT Tweets

About Gravity Analytica

Recent News

  • 01.22.2025 - Holding(s) in Company

Recent Filings

    RNS Number : 2437L
    MaxCyte, Inc.
    07 November 2024

    MaxCyteannounces filing of Form 10-Q for the quarterly period endedSeptember 30, 2024

    ROCKVILLE, MD,November 7, 2024-MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and innovative bioprocessing applications, today announced that it has filed a Form 10-Q with theSECfor the quarterly period endedSeptember 30, 2024.

    A copy of the Form 10-Q is available to view on theSEC'swebsite atwww.sec.govand has also been posted to the "SECfilings" page of the Company's website,https://investors.maxcyte.com/

    AboutMaxCyte

    AtMaxCyte, we pursue cell engineering excellence to maximize the potential of cells to improve patients' lives. We have spent more than 20 years honing our expertise by building best-in-class platforms, perfecting the art of the transfection workflow, and venturing beyond today's processes to innovate tomorrow's solutions. Our ExPERTTM platform, which is based on our Flow Electroporation® technology, has been designed to support the rapidly expanding cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes: four instruments, the ATxTM, STxTM, GTxTM and VLxTM; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a robust worldwide intellectual property portfolio. By providing our partners with the right technology platform, as well as scientific, technical, and regulatory support, we aim to guide them on their journey to transform human health. Learn more atmaxcyte.comand follow us on X and LinkedIn.

    MaxCyte Contacts:

    US IR Adviser

    Gilmartin Group

    David Deuchler, CFA

    +1 415-937-5400

    ir@maxcyte.com

    Nominated Adviser and Joint Corporate Broker

    Panmure Liberum

    Emma Earl/Freddy Crossley

    Corporate Broking

    Rupert Dearden

    +44 (0)20 7886 2500

    UKIR Adviser

    ICR Healthcare

    Mary-Jane Elliott

    Chris Welsh

    +44 (0)203 709 5700

    maxcyte@icrhealthcare.com

    This information is provided by RNS, the news service of theLondon Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in theUnited Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contactrns@lseg.comor visitwww.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and theLondon Stock Exchangeuse the personal data you provide us, please see ourPrivacy Policy.
    END
    DOCQKABNOBDDFDK
    Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com